appear to characterize RF-positive/CCP-positive patients]. To be sure, 82% of patients who are RF positive and anti-CCP negative have ACR50 response rates vs 43% of anti-CCP-positive-only subjects. However, only seven patients are anti-CCP positive/RF negative, and most anti-CCP-positive patients have response rates similar to those of RF-positive patients.
The reference of Carson et al. [2] , cited to support the suggestion that treatment with rituximab can have a major effect on RF-producing B-cell clones and less so on anti-CCP-producing B-cell clones, was published in 1991, before reports of anti-CCP antibodies. Any slightly differential effect of rituximab on biological markers may be explained by an overall effect on inflammation rather than only on B-cells, as larger decreases in RF than anti-CCP titres have also been described after treatment with infliximab [3, 4] or adalimumab [5] .
Finally, we have substantial concern about the value of prediction of responses to any therapy in groups of patients, according to any variable, to a physician caring for an individual patient. Of course, there are situations in which the prognosis of a poor response is clinically useful-most obviously for antibiotics with no (zero) antimicrobial activity against a given pathogen. But in this study, the group with the least likelihood of a response, patients who were negative for both RF and anti-CCP, had a response rate of 21%. A 1 in 5 likelihood of a response in a patient who has failed several other biological agents would appear a reasonable treatment option. We would treat such a patient, and would be concerned that reimbursement authorities would use data from groups to potentially deny treatment to individuals who really need it and might derive benefit. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis: reply SIR, We appreciate the interest of Dr Belmonte Serrano and Dr Pincus [1] in our work, and we would like to further clarify and reinforce the message of our paper based on the present results in our hands [2] . Large, randomized controlled trials [3, 4] provided some information regarding the better clinical response that can be observed in seropositive, i.e. RF-and/or anti-CCP-positive, RA patients under rituximab treatment, if compared with seronegative RA. Our work confirms these observations in a real-life cohort of Italian RA patients, further distinguishing that the laboratory predictor may be represented by RF, rather than anti-CCP positivity [2] . When considering the increasing spectrum of biological therapies available now and probably in the near future for RA, predictors of response are crucial to address the choice of the best biological therapy in the single case. Thus, in our opinion, the main question is not whether RF-negative patients will respond or not to rituximab, but which RA patient the rheumatologist should treat earlier with rituximab. RF positivity was the laboratory item associated with a significant clinical response to rituximab in our retrospective study [2] .
Separate univariate logistic regression analyses were performed, where alternatively the presence of RF or anti-CCP antibodies was the independent variable tested, and the ACR 50 response or the European League Against Rheumatism (EULAR) moderate/good response was the dependent variable in the models. RF was significantly associated with both the ACR 50 response [P ¼ 0.0003; odds ratio (OR) ¼ 7.519; 95% CI 2.521, 22.426] and EULAR moderate/good response (P ¼ 0.001; OR ¼ 5.909; 95% CI 1.997, 17.483), whereas the anti-CCP antibodies were associated with the ACR 50 response, but with a low level of significance (P ¼ 0.049; OR ¼ 2.600; 95% CI 1.004, 6.736) and clearly not associated with the EULAR moderate/good response (P ¼ 0.322). In addition, statistical analyses with two distinct stepwise regression models, where anti-CCP or RF was separately introduced, were also performed, and confirmed the absence of redundancy. In the first model, where anti-CCP was included and RF excluded in the pool of tested variables (the same as included in the paper) [1] , anti-CCP was not selected. Conversely, in the second model where anti-CCP was excluded and RF included, RF was selected (P ¼ 0.001) both for the ACR 50, and EULAR moderate/good response, thus reinforcing the concept that the presence of RF and not the presence of anti-CCP was associated with major response to rituximab in our RA cohort. Finally, this result was recently confirmed by other independent groups [5] [6] [7] [8] .
Although in our study the RF-negative RA subset included a higher number of patients who failed more than one anti-TNF agent, if compared with the RF-positive subset, no difference was observed as regards baseline disease activity or baseline disability between the two groups of patients, as stated [2] . The mechanism involved in a putative anti-TNF-mediated resistance to rituximab deserves further investigation, and we provided some preliminary support to the notion that the duration of the exposure to anti-TNF therapy may also be relevant [2] .
The conclusion of our paper that 'RF-positive patients with baseline lower disability may be best candidates for rituximab' [2] clarifies that the presence of the RF may be relevant for the choice of rituximab therapy after the failure of the first anti-TNF agent. RF-negative patients may as well respond to rituximab, but other biologicals may work better in such cases [9] . However, pharmacogenetic studies, also in course by our Group, might provide additional insights for the choice [10]. 
